Contemporary anticoagulation therapy in patients undergoing percutaneous intervention

References

• Horne M. Overview of hemostasis and thrombosis; current status of antithrombotic therapies. Thromb Res 2005;117(1-2):15-17; discussion 39-42
   PubMedGoogle Scholar
• Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006;32(Suppl 1):32:8
   PubMed Web of Science ®Google Scholar
• Linkins LA, Julian JA, Rischke J, et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002;107(5):241-4
   PubMedGoogle Scholar
• El Rouby S, Cohen M, Gonzales A, et al. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures. J Thromb Thrombolysis 2006;21(2):137-45
   PubMedGoogle Scholar
• Silvain J, Beygui F, Ankri A, et al. Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J Am Coll Cardiol 2010;55(7):617-25
   PubMed Web of Science ®Google Scholar
• Inchiosa MA Jr, Pothula S, Kubal K, et al. Toward development of a point-of-care assay of enoxaparin anticoagulant activity in whole blood. J Thromb Thrombolysis 2011;32(1):47-53
   PubMedGoogle Scholar
• Marmur JD, Poludasu S, Feit A, et al. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention. J Invasive Cardiol 2008;20(7):323-7
   PubMedGoogle Scholar
• Faxon DP. Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheter Cardiovasc Interv 2013;79(2):181-97
   Google Scholar
• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133(Suppl 6):141S-59S
   Web of Science ®Google Scholar
• Hirsh J, Anand SS, Halperin JL, Fuster V. AHA Scientific statement: guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol 2001;21(7):E9-
   Google Scholar
• Fazavana J, Bianchini EP, Saller F, et al. A chemically-modified inactive antithrombin as a potent antagonist of fondaparinux and heparin anticoagulant activity. J Thromb Haemost 2013;11(6):1128-36
   PubMedGoogle Scholar
• Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287(7):324-7
   PubMed Web of Science ®Google Scholar
• Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315(18):1109-14
   PubMed Web of Science ®Google Scholar
• Kaplan K, Davison R, Parker M, et al. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1987;59(4):241-4
   PubMedGoogle Scholar
• Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for cardiovascular angiography and interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50(7):e1-e157
   PubMedGoogle Scholar
• De Caterina R, Husted S, Wallentin L, et al. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;109(5):769-86
   PubMedGoogle Scholar
• Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289(7):853-63
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141(3):348-52
   PubMedGoogle Scholar
• Ostadal P, Alan D, Vejvoda J, et al. Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome. Exp Clin Cardiol 2008;13(4):175-8
   PubMedGoogle Scholar
• Alwi I. The role of low-molecular-weight heparins in the management of unstable angina and non-ST elevation myocardial infarction. Acta Med Indones 2008;40(4):228-32
   PubMedGoogle Scholar
• Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-q-wave coronary events study group. N Engl J Med 1997;337(7):447-52
   PubMed Web of Science ®Google Scholar
• Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292(1):45-54
   PubMed Web of Science ®Google Scholar
• Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The antithrombotic combination using tirofiban and enoxaparin. Am Heart J 2002;144(3):470-7
   PubMedGoogle Scholar
• Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the coronary revascularization using integrilin and single bolus enoxaparin study. J Am Coll Cardiol 2003;41(1):20-5
   PubMedGoogle Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58(24):e44-122
   PubMed Web of Science ®Google Scholar
• White HD, Gallo R, Cohen M, et al. The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. Am Heart J 2009;157(1):125-31
   PubMedGoogle Scholar
• Montalescot G, Gallo R, White HD, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv 2009;2(11):1083-91
   PubMed Web of Science ®Google Scholar
• Collet JP, Huber K, Cohen M, et al. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). Am J Cardiol 2013;112(9):1367-72
   PubMedGoogle Scholar
• Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50(18):1742-51
   PubMed Web of Science ®Google Scholar
• Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31(20):2501-55
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008;99(5):830-9
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355(21):2203-16
   PubMed Web of Science ®Google Scholar
• Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86(2):385-91
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358(21):2218-30
   PubMed Web of Science ®Google Scholar
• Deeks ED, Curran MP. Bivalirudin: in patients with acute coronary syndromes : planned for urgent or early intervention. Drugs 2008;68(16):2345-56
   PubMedGoogle Scholar
• Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009;135(6):1651-64
   PubMedGoogle Scholar
• Skrupky LP, Smith JR, Deal EN, et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy 2010;30(12):1229-38
   PubMedGoogle Scholar
• Schulz S, Mehilli J, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010;31(5):582-7
   PubMedGoogle Scholar
• Rossig L, Genth-Zotz S, Rau M, et al. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study. Int J Cardiol 2011;148(2):214-19
   PubMedGoogle Scholar
• Dhillon S. Argatroban: a review of its use in the management of heparin-induced thrombocytopenia. Am J Cardiovasc Drugs 2009;9(4):261-82
   PubMedGoogle Scholar
• Fitchett D, Verma A, Eikelboom J, et al. Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: the clinical dilemma of triple therapy. Curr Opin Cardiol 2013;29(1):1-9
   Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381(9872):1107-15
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28(13):1598-660
   PubMed Web of Science ®Google Scholar
• Gibson CM, Ten Y, Murphy SA, et al. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (a REPLACE-2 analysis). Am J Cardiol 2007;99(12):1687-90
   PubMedGoogle Scholar
• White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;51(18):1734-41
   PubMedGoogle Scholar
• Dangas GD, Mehran R, Nikolsky E, et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011;57(23):2309-16
   PubMedGoogle Scholar
• Allie DE, Hall P, Shammas NW, et al. The angiomax peripheral procedure registry of vascular events trial (APPROVE): in-hospital and 30-day results. J Invasive Cardiol 2004;16(11):651-6
   PubMedGoogle Scholar
• Kasapis C, Gurm HS, Chetcuti SJ, et al. Defining the optimal degree of heparin anticoagulation for peripheral vascular interventions: insight from a large, regional, multicenter registry. Circ Cardiovasc Interv 2010;3(6):593-601
   PubMedGoogle Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113(11):e463-654
   PubMed Web of Science ®Google Scholar
• Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;58(19):2020-45
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease. Int Angiol 2007;26(2):81-157
   PubMed Web of Science ®Google Scholar
• Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363(17):1597-607
   PubMed Web of Science ®Google Scholar
• Chessa M, Carminati M, Butera G, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002;39(6):1061-5
   PubMedGoogle Scholar
• Vahanian A, Alfieri O, Al-Attar N, et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Euro Intervention 2008;4(2):193-9
   Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010;104(1):49-60
   PubMed Web of Science ®Google Scholar
• Lassen MR. Recent developments in the use of oral anticoagulants. Expert Opin Pharmacother 2009;10(11):1769-81
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. identifier: NCT00818753. Available from: http://clinicaltrials.gov/show/NCT00818753
   Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9-19
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. identifier: NCT01442792. Available from: http://clinicaltrials.gov/show/NCT01442792
   Google Scholar
• Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119(22):2877-85
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365(8):699-708
   PubMed Web of Science ®Google Scholar
• Howard EL, Becker KC, Rusconi CP, Becker RC. Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol 2007;27(4):722-7
   PubMed Web of Science ®Google Scholar
• Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008;117(22):2865-74
   PubMed Web of Science ®Google Scholar
• Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010;122(6):614-22
   PubMed Web of Science ®Google Scholar
• Kishimoto TK, Qi YW, Long A, et al. M118–a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb Haemost 2009;102(5):900-6
   PubMedGoogle Scholar
• Rao SV, Melloni C, Myles-Dimauro S, et al. Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial. Circulation 2010;121(15):1713-21
   PubMedGoogle Scholar
• Li YH, Shi GY, Wu HL. Thrombomodulin in the treatment of atherothrombotic diseases. Front Biosci (Schol Ed) 2009;1:33-8
   PubMedGoogle Scholar
• Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290(2):238-47
   PubMed Web of Science ®Google Scholar
• Matyal R, Mahmood F, Park KW. Tifacogin, recombinant tissue factor pathway inhibitor. Int Anesthesiol Clin 2005;43(2):135-44
   PubMedGoogle Scholar
• Lassen MR, Dahl O, Mismetti P, et al. SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol 2008;51(15):1498-504
   PubMedGoogle Scholar
• Paccaly A, Frick A, Rohatagi S, et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol 2006;46(1):37-44
   PubMedGoogle Scholar
• Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115(20):2642-51
   PubMed Web of Science ®Google Scholar
• Steg PG, Mehta SR, Pollack CV Jr, et al. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 2013;310(11):1145-55
   PubMed Web of Science ®Google Scholar
• Alexander JH, Dyke CK, Yang H, et al. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. J Thromb Haemost 2004;2(2):234-41
   PubMedGoogle Scholar
• Becker RC, Alexander JH, Dyke C, et al. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease. Thromb Res 2006;117(4):439-46
   PubMedGoogle Scholar
• Giugliano RP, Wiviott SD, Stone PH, et al. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol 2007;49(25):2398-407
   PubMed Web of Science ®Google Scholar
• Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003;41(12):2147-53
   PubMed Web of Science ®Google Scholar
• Fox KA, Steg PG, Eagle KA, et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297(17):1892-900
   PubMed Web of Science ®Google Scholar